<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Antibodies against β(2)-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (anti-β(2)GPI) are one of the hallmarks of the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="1" pm="."><plain>However, they are heterogenic regarding their <z:chebi fb="0" ids="53000">epitope</z:chebi> specificity, pathogenic mechanisms and their avidity </plain></SENT>
<SENT sid="2" pm="."><plain>In the current study we present some outstanding issues about avidity of anti-β(2)GPI antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Our results confirmed that high avidity anti-β(2)GPI are associated with <z:mp ids='MP_0005048'>thrombosis</z:mp> and APS, while in low avidity anti-β(2)GPI group non-APS (predominantly <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>) patients prevailed </plain></SENT>
</text></document>